Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15724378 | 0.86 | LMNA (0.55) | HTTLMNASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL15730738 | 0.84 | MKNK1 (0.53) | HTTLMNASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL15730873 | 0.81 | LMNA (0.60) | HTTLMNASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL15730118 | 0.79 | PTGS2 (0.67) | MKNK1MKNK2PTGS1PTGS2 | |
| SCHEMBL15730256 | 0.78 | CA2 (0.62) | MKNK1MKNK2PTGS1PTGS2 | |
| SCHEMBL15730108 | 0.75 | DRD1 (0.54) | HTTLMNASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL15730136 | 0.73 | LMNA (0.53) | HTTLMNASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5023540 | 0.73 | HTT (0.73) | HTTLMNASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL7662428 | 0.73 | MKNK1 (0.61) | HTTLMNASMN1; SMN2ALDH1A1MKNK1 | |
| SCHEMBL19925346 | 0.72 | MKNK1 (0.57) | LMNASMN1; SMN2ALDH1A1MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HTT 4049/4885LMNA 3182/4885SMN1; SMN2 3500/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HTT 4049/4885LMNA 3182/4885SMN1; SMN2 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.